Sponsored by
This is early work but sounds exciting. I wish them luck.
This is the International Brain Tumor Association E-news letter. The Musella Foundation is not related to this organization - we are just passing it along (with thier permission) because it should be of interest to you!
This is for a rare pediatric brain tumor - but it is the first drug ever designed specifically for pediatric brain tumors!
This is one of the most important articles of the year. It discusses the results of the first small ICT-107 vaccine trial. The key outcome: "At a median follow-up of 40.1 months, six of 16 newly diagnosed GBM patients showed no evidence of tumor recurrence. "
Notice the Acknowledgments section: This study was supported by funding from Musella Foundation For Brain Tumor Research & Information, Inc. and ImmunoCellular Therapeutics Ltd.
This confirms that we (The Musella Foundation) seek out and fund the best research. Not only did we fund this project, but we also funded the early development on one of the targets of the vaccine. This is a perfect example of how important YOUR donations are. People always ask me if making donations can make a difference. This proves it.
This has nothing to do with the Musella Foundation... but I am sending it because it may be of interest. Good lineup of speakers.
This is an announcement about events at the Monmouth Medical Center, NJ. Nothing to do with the Musella Foundation but may be of interest to you!
This is one of the more promising new treatments out there... I am keeping an eye on it.
This study shows that smokers do worse after brain tumor surgery, and that quitting helps.
Fascinating video interview of Dr Keith Black, from Cedars Sinai, about the ICT-107 vaccine trial
Describes this new, FDA approved treatment for brain tumors: Includes a nice video of a patient using the Novocure NOVO TTF100A device. For more details on the Novocure device, visit: http://virtualtrials.com/novocure
